Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Atezolizumab & Bladder Cancer, Atezolizumab is approved by both the FDA and EMA for advanced urothelial carcinoma (the main histology in bladder cancer), but with important restriction and label-change details (1, 2, 3). In May 2016, the US FDA approved atezolizumab, an anti-PD-L1 antibody, marking it as the first immune-checkpoint inhibitor for patients with Bladder Cancer (8).
Avelumab has demonstrated encouraging antitumor activity and maintains a manageable safety profile in patients with Bladder Cancer. Its d…